Dianthus Therapeutics (DNTH) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $72.09, -3.27% vs the prior close of $74.53.
- Volume 1.05M shares, 1.3x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
DNTH slides 3.3% to $72.09, a 6-month low, 11 down days in a row. Closed at $72.09, -3.27% vs the prior close of $74.53. Day range $69.43–$75.34, opened at $74.41.
DNTH daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — DNTH slides 3.3% to $72.09, a 6-month low, 11 down days in a row
- Closed at $72.09, -3.27% vs the prior close of $74.53. Day range $69.43–$75.34, opened at $74.41.
- Volume was 1.05M shares, 1.3x its 50-day average of 786.48K.
- Price is -27.4% vs its 50-day average ($99.32) and -13.2% vs its 200-day average ($83.06).
- 52-week range $32.22–$117.88; today's close sits at 47% of that range, 38.8% below the 52-week high.
- That makes 11 straight losses.
Oct 15, 2026 — DNTH dips 0.3% to $74.53, a 6-month low, 10 down days in a row
- Closed at $74.53, -0.31% vs the prior close of $74.76. Day range $72.67–$77.55, opened at $75.77.
- Volume was 943.60K shares, 1.2x its 50-day average of 788.65K.
- Price is -25.5% vs its 50-day average ($100.07) and -10.1% vs its 200-day average ($82.90).
- 52-week range $32.22–$117.88; today's close sits at 49% of that range, 36.8% below the 52-week high.
- That makes 10 straight losses.
Oct 14, 2026 — DNTH slides 3.6% to $74.76, a 6-month low, 9 down days in a row
- Closed at $74.76, -3.63% vs the prior close of $77.58. Day range $74.47–$78.78, opened at $77.17.
- Volume was 977.30K shares, 1.3x its 50-day average of 781.83K.
- Price is -25.9% vs its 50-day average ($100.83) and -9.6% vs its 200-day average ($82.74).
- 52-week range $32.22–$117.88; today's close sits at 50% of that range, 36.6% below the 52-week high.
- That makes 9 straight losses.
Oct 13, 2026 — DNTH slides 4.9% to $77.58, a 3-month low, 8 down days in a row
- Closed at $77.58, -4.89% vs the prior close of $81.57. Day range $77.25–$81.46, opened at $81.42.
- Volume was 1.32M shares, 1.7x its 50-day average of 772.36K.
- Price is -23.6% vs its 50-day average ($101.55) and -6.0% vs its 200-day average ($82.57).
- 52-week range $32.22–$117.88; today's close sits at 53% of that range, 34.2% below the 52-week high.
- That makes 8 straight losses.
Oct 12, 2026 — DNTH dips 1.0% to $81.57, a 3-month low, 7 down days in a row
- Closed at $81.57, -0.97% vs the prior close of $82.37. Day range $80.91–$83.77, opened at $81.77.
- Volume was 853.90K shares, 1.1x its 50-day average of 776.80K.
- Price is -20.1% vs its 50-day average ($102.12) and -1.0% vs its 200-day average ($82.40).
- 52-week range $32.22–$117.88; today's close sits at 58% of that range, 30.8% below the 52-week high.
- That makes 7 straight losses.
Oct 9, 2026 — DNTH ends flat (-0.1%) to $82.37, a 3-month low, 6 down days in a row
- Closed at $82.37, -0.07% vs the prior close of $82.43. Day range $82.13–$85.20, opened at $82.36.
- Volume was 738.90K shares, 0.9x its 50-day average of 780.60K.
- Price is -19.7% vs its 50-day average ($102.62) and +0.2% vs its 200-day average ($82.21).
- 52-week range $32.22–$117.88; today's close sits at 59% of that range, 30.1% below the 52-week high.
- That makes 6 straight losses.
Oct 8, 2026 — DNTH dips 2.9% to $82.43, a 3-month low, 5 down days in a row
- Closed at $82.43, -2.89% vs the prior close of $84.88. Day range $81.06–$84.85, opened at $84.73.
- Volume was 1.00M shares, 1.3x its 50-day average of 778.27K.
- Price is -20.1% vs its 50-day average ($103.23) and +0.5% vs its 200-day average ($82.01).
- 52-week range $32.22–$117.88; today's close sits at 59% of that range, 30.1% below the 52-week high.
- That makes 5 straight losses.
Oct 7, 2026 — DNTH dips 0.6% to $84.88, a 3-month low, 4 down days in a row
- Closed at $84.88, -0.61% vs the prior close of $85.40. Day range $84.13–$86.61, opened at $84.60.
- Volume was 562.50K shares, 0.7x its 50-day average of 783.84K.
- Price is -18.1% vs its 50-day average ($103.66) and +3.7% vs its 200-day average ($81.81).
- 52-week range $32.22–$117.88; today's close sits at 61% of that range, 28.0% below the 52-week high.
- That makes 4 straight losses.
Oct 6, 2026 — DNTH dips 3.0% to $85.40, a 3-month low, 3 down days in a row
- Closed at $85.40, -3.00% vs the prior close of $88.04. Day range $83.19–$88.58, opened at $88.58.
- Volume was 1.35M shares, 1.8x its 50-day average of 769.09K.
- Price is -17.9% vs its 50-day average ($104.00) and +4.7% vs its 200-day average ($81.60).
- 52-week range $32.22–$117.88; today's close sits at 62% of that range, 27.6% below the 52-week high.
- That makes 3 straight losses.
Oct 5, 2026 — DNTH ends flat (-0.2%) to $88.04
- Closed at $88.04, -0.19% vs the prior close of $88.21. Day range $86.09–$89.58, opened at $88.44.
- Volume was 597.40K shares, 0.8x its 50-day average of 773.69K.
- Price is -15.7% vs its 50-day average ($104.38) and +8.2% vs its 200-day average ($81.38).
- 52-week range $32.22–$117.88; today's close sits at 65% of that range, 25.3% below the 52-week high.
Oct 2, 2026 — DNTH ends flat (-0.1%) to $88.21
- Closed at $88.21, -0.12% vs the prior close of $88.32. Day range $87.73–$91.24, opened at $89.05.
- Volume was 751.40K shares, 1.0x its 50-day average of 776.34K.
- Price is -15.7% vs its 50-day average ($104.69) and +8.7% vs its 200-day average ($81.14).
- 52-week range $32.22–$117.88; today's close sits at 65% of that range, 25.2% below the 52-week high.
DNTH latest news & SEC filings
Every SEC filing by or about DNTH in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 18, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Carr Edward converted options/RSUs into 20,000 shares at $17.88 (≈$357.60K) on Sep 17, 2026; now holds 20,000
- Carr Edward sold 7,928 shares at $100.43 (≈$796.21K) on Sep 17, 2026; now holds 12,072
- Carr Edward sold 6,771 shares at $101.37 (≈$686.38K) on Sep 17, 2026; now holds 5,301
- Carr Edward sold 3,501 shares at $102.39 (≈$358.47K) on Sep 17, 2026; now holds 1,800
- Carr Edward sold 1,100 shares at $103.20 (≈$113.52K) on Sep 17, 2026; now holds 700
- Carr Edward sold 700 shares at $104.39 (≈$73.07K) on Sep 17, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 18, 2026 · Form S-3ASR — S-3ASR filing
S-3ASR filing
An offering document: new shares or debt may be sold, which can increase the share count (dilution) or debt load. Size and terms are in the prospectus.
Sep 17, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Sep 3, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Randhawa Simrat sold 2,600 shares at $105.19 (≈$273.49K) on Sep 1, 2026
- Randhawa Simrat sold 7,215 shares at $106.25 (≈$766.59K) on Sep 1, 2026
- Randhawa Simrat sold 13,309 shares at $106.74 (≈$1.42M) on Sep 1, 2026
- Randhawa Simrat sold 2,600 shares at $105.19 (≈$273.49K) on Sep 1, 2026
- Randhawa Simrat sold 7,215 shares at $106.25 (≈$766.59K) on Sep 1, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Sep 1, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 19, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 14, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 13, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 7, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 7, 2026 · Form SCHEDULE 13G — Passive stake (13G)
Passive stake (13G) — an investor reported owning more than 5%
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 4, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$50.22M (prior year -$31.63M) (loss widened vs Jun 30, 2025)
- Diluted EPS: -$0.90 (prior year -$0.88) (loss widened vs Jun 30, 2025)
Aug 4, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jul 28, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade DNTH
- Last results release: Aug 4, 2026 (8-K Item 2.02). Previous ones: May 5, 2026, Mar 9, 2026, Jan 12, 2026. Based on that rhythm, the next report is likely around Nov 3, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 1.77% (largest 5.0%).
- Liquidity: about 906.19K shares (≈$65.33M) trade per day on average.
- 52-week position: $72.09 vs a range of $32.22–$117.88 (47% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 25 sales; latest: Edward Carr sold 7,928 shares on Sep 17, 2026.
- Latest filings: 10-Q Aug 4, 2026; 8-K Aug 4, 2026; 8-K Jun 12, 2026.
- Share count: 55.93M shares outstanding (Aug 3, 2026), +73.8% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
DNTH market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 74.41 | 75.34 | 69.43 | 72.09 | 1.05M |
| Oct 15, 2026 | 75.77 | 77.55 | 72.67 | 74.53 | 943.60K |
| Oct 14, 2026 | 77.17 | 78.78 | 74.47 | 74.76 | 977.30K |
| Oct 13, 2026 | 81.42 | 81.46 | 77.25 | 77.58 | 1.32M |
| Oct 12, 2026 | 81.77 | 83.77 | 80.91 | 81.57 | 853.90K |
| Oct 9, 2026 | 82.36 | 85.20 | 82.13 | 82.37 | 738.90K |
| Oct 8, 2026 | 84.73 | 84.85 | 81.06 | 82.43 | 1.00M |
| Oct 7, 2026 | 84.60 | 86.61 | 84.13 | 84.88 | 562.50K |
| Oct 6, 2026 | 88.58 | 88.58 | 83.19 | 85.40 | 1.35M |
| Oct 5, 2026 | 88.44 | 89.58 | 86.09 | 88.04 | 597.40K |
| Oct 2, 2026 | 89.05 | 91.24 | 87.73 | 88.21 | 751.40K |
| Oct 1, 2026 | 88.40 | 91.04 | 87.22 | 88.32 | 767.00K |
| Sep 30, 2026 | 88.19 | 90.71 | 87.58 | 88.05 | 1.03M |
| Sep 29, 2026 | 87.40 | 87.69 | 84.72 | 87.16 | 1.03M |
| Sep 28, 2026 | 88.03 | 89.14 | 87.04 | 87.83 | 652.70K |
| Sep 25, 2026 | 91.56 | 92.89 | 88.34 | 88.55 | 522.70K |
| Sep 24, 2026 | 93.75 | 94.95 | 90.36 | 90.71 | 726.20K |
| Sep 23, 2026 | 98.35 | 98.53 | 89.78 | 93.44 | 1.19M |
| Sep 22, 2026 | 96.84 | 100.47 | 96.55 | 98.35 | 1.12M |
| Sep 21, 2026 | 95.95 | 99.67 | 94.58 | 96.47 | 933.20K |
About Dianthus Therapeutics
Dianthus Therapeutics (DNTH) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in NEW YORK, NY. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1690585.
DNTH board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Marino Garcia | CEO AND PRESIDENT | Aug 7, 2026 |
| Sujay Kango | Director | May 22, 2026 |
| Alison Frances Lawton | Director | May 22, 2026 |
| Anne Mcgeorge | Director | Aug 11, 2026 |
| Simon Read | Director | Aug 19, 2026 |
| Steven J. Romano | Director | May 22, 2026 |
| Paula Soteropoulos | Director | May 22, 2026 |
| Jonathan Violin | Director | May 22, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Edward Carr | CHIEF ACCOUNTING OFFICER | Sep 18, 2026 |
| Marino Garcia | CEO AND PRESIDENT | Aug 7, 2026 |
| Simrat Randhawa | EVP, Head of R&D | Sep 3, 2026 |
| Ryan Savitz | EVP, CFO & CBO | Jul 13, 2026 |
| Adam M Veness | SVP, General Counsel and Sec. | Aug 14, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Sep 17, 2026 | Edward Carr | Sale | 7,928 | $100.43 |
| Sep 17, 2026 | Edward Carr | Sale | 6,771 | $101.37 |
| Sep 17, 2026 | Edward Carr | Sale | 3,501 | $102.39 |
| Sep 17, 2026 | Edward Carr | Sale | 700 | $104.39 |
| Sep 17, 2026 | Edward Carr | Sale | 1,100 | $103.20 |
| Sep 17, 2026 | Edward Carr | Sale | 7,928 | $100.43 |
| Sep 17, 2026 | Edward Carr | Sale | 6,771 | $101.37 |
| Sep 17, 2026 | Edward Carr | Sale | 3,501 | $102.39 |
| Sep 17, 2026 | Edward Carr | Sale | 700 | $104.39 |
| Sep 17, 2026 | Edward Carr | Sale | 1,100 | $103.20 |
| Sep 17, 2026 | Edward Carr | Sale | 7,928 | $100.43 |
| Sep 17, 2026 | Edward Carr | Sale | 6,771 | $101.37 |
| Sep 17, 2026 | Edward Carr | Sale | 3,501 | $102.39 |
| Sep 17, 2026 | Edward Carr | Sale | 700 | $104.39 |
| Sep 17, 2026 | Edward Carr | Sale | 1,100 | $103.20 |
DNTH financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $2.04M | $-162.34M | -4.20 | $-129.06M |
| Dec 31, 2024 | $6.24M | $-84.97M | -2.55 | $-78.18M |
| Dec 31, 2023 | $2.83M | $-43.55M | -8.45 | $-36.86M |
| Dec 31, 2022 | — | $-28.48M | -32.57 | $-29.07M |
| Dec 31, 2021 | — | $-71.14M | -1.29 | $-59.53M |
Latest balance sheet: total assets $1.21B, total liabilities $41.25M, cash $110.55M (as of Jun 30, 2026).
DNTH earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 4, 2026 | 8-K Item 2.02 (results) | $110.40 |
| May 5, 2026 | 8-K Item 2.02 (results) | $90.24 |
| Mar 9, 2026 | 8-K Item 2.02 (results) | $79.23 |
| Jan 12, 2026 | 8-K Item 2.02 (results) | $39.12 |
| Nov 5, 2025 | 8-K Item 2.02 (results) | $33.73 |
| Oct 16, 2025 | 8-K Item 2.02 (results) | $36.00 |
| Aug 7, 2025 | 8-K Item 2.02 (results) | $19.15 |
| May 12, 2025 | 8-K Item 2.02 (results) | $20.08 |
| Mar 11, 2025 | 8-K Item 2.02 (results) | $23.38 |
| Nov 7, 2024 | 8-K Item 2.02 (results) | $29.90 |
| Aug 8, 2024 | 8-K Item 2.02 (results) | — |
| May 9, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on DNTH
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.